Loading...

Seattle Genetics

Nasdaq:SGEN
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
SGEN
Nasdaq
$11B
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Seattle Genetics, Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The last earnings update was 50 days ago. More info.


Add to Portfolio Compare Print
SGEN Share Price and Events
7 Day Returns
-2.9%
NasdaqGS:SGEN
-0.6%
US Biotechs
0.5%
US Market
1 Year Returns
5.2%
NasdaqGS:SGEN
-8.8%
US Biotechs
0.8%
US Market
SGEN Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Seattle Genetics (SGEN) -2.9% 3.8% -8.2% 5.2% 82% 65.3%
US Biotechs -0.6% -0.9% -9.1% -8.8% 11.6% 4.7%
US Market 0.5% 0.2% 1.1% 0.8% 37.4% 37.5%
1 Year Return vs Industry and Market
  • SGEN outperformed the Biotechs industry which returned -8.8% over the past year.
  • SGEN outperformed the Market in United States of America which returned 0.8% over the past year.
Price Volatility
SGEN
Industry
5yr Volatility vs Market

SGEN Value

 Is Seattle Genetics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Seattle Genetics to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Seattle Genetics.

NasdaqGS:SGEN Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 15 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 10%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGS:SGEN
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.32
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.318 (1 + (1- 21%) (0.61%))
1.217
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.22
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (1.217 * 5.96%)
9.99%

Discounted Cash Flow Calculation for NasdaqGS:SGEN using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Seattle Genetics is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

NasdaqGS:SGEN DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 9.99%)
2019 -130.00 Analyst x3 -118.20
2020 106.50 Analyst x2 88.04
2021 298.10 Analyst x2 224.05
2022 484.73 Analyst x2 331.25
2023 812.16 Analyst x2 504.61
2024 1,106.07 Est @ 36.19% 624.83
2025 1,395.32 Est @ 26.15% 716.67
2026 1,662.17 Est @ 19.12% 776.22
2027 1,898.31 Est @ 14.21% 806.01
2028 2,102.63 Est @ 10.76% 811.71
Present value of next 10 years cash flows $4,765.21
NasdaqGS:SGEN DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $2,102.63 × (1 + 2.73%) ÷ (9.99% – 2.73%)
$29,770.30
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $29,770.30 ÷ (1 + 9.99%)10
$11,492.71
NasdaqGS:SGEN Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $4,765.21 + $11,492.71
$16,257.92
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $16,257.92 / 161.31
$100.78
NasdaqGS:SGEN Discount to Share Price
Calculation Result
Value per share (USD) From above. $100.78
Current discount Discount to share price of $68.50
= -1 x ($68.50 - $100.78) / $100.78
32%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Seattle Genetics is available for.
Intrinsic value
32%
Share price is $68.5 vs Future cash flow value of $100.78
Current Discount Checks
For Seattle Genetics to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Seattle Genetics's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Seattle Genetics's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Seattle Genetics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Seattle Genetics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGS:SGEN PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-0.78
NasdaqGS:SGEN Share Price ** NasdaqGS (2019-06-14) in USD $68.5
United States of America Biotechs Industry PE Ratio Median Figure of 35 Publicly-Listed Biotechs Companies 19.23x
United States of America Market PE Ratio Median Figure of 3,091 Publicly-Listed Companies 17.68x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Seattle Genetics.

NasdaqGS:SGEN PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:SGEN Share Price ÷ EPS (both in USD)

= 68.5 ÷ -0.78

-88.06x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Seattle Genetics is loss making, we can't compare its value to the US Biotechs industry average.
  • Seattle Genetics is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Seattle Genetics's expected growth come at a high price?
Raw Data
NasdaqGS:SGEN PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -88.06x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 15 Analysts
80.4%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 26 Publicly-Listed Biotechs Companies 1.08x
United States of America Market PEG Ratio Median Figure of 2,125 Publicly-Listed Companies 1.52x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Seattle Genetics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Seattle Genetics's assets?
Raw Data
NasdaqGS:SGEN PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $8.15
NasdaqGS:SGEN Share Price * NasdaqGS (2019-06-14) in USD $68.5
United States of America Biotechs Industry PB Ratio Median Figure of 425 Publicly-Listed Biotechs Companies 2.9x
United States of America Market PB Ratio Median Figure of 5,244 Publicly-Listed Companies 1.79x
NasdaqGS:SGEN PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:SGEN Share Price ÷ Book Value per Share (both in USD)

= 68.5 ÷ 8.15

8.4x

* Primary Listing of Seattle Genetics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Seattle Genetics is overvalued based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Seattle Genetics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Seattle Genetics has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

SGEN Future Performance

 How is Seattle Genetics expected to perform in the next 1 to 3 years based on estimates from 15 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
80.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Seattle Genetics expected to grow at an attractive rate?
  • Seattle Genetics's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Seattle Genetics's earnings growth is expected to exceed the United States of America market average.
  • Seattle Genetics's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGS:SGEN Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGS:SGEN Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 15 Analysts 80.4%
NasdaqGS:SGEN Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 15 Analysts 26%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 22.6%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 18%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.9%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGS:SGEN Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 15 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGS:SGEN Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 2,235 648 756 8
2022-12-31 1,768 389 443 8
2021-12-31 1,319 199 102 11
2020-12-31 1,041 28 -80 14
2019-12-31 816 -80 -181 15
NasdaqGS:SGEN Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 709 -114 -124
2018-12-31 655 -204 -223
2018-09-30 610 -182 -162
2018-06-30 576 -179 -45
2018-03-31 514 -203 -177
2017-12-31 482 -119 -126
2017-09-30 458 -132 -121
2017-06-30 429 -155 -203
2017-03-31 416 -143 -180
2016-12-31 418 -97 -140
2016-09-30 406 -101 -110
2016-06-30 384 -110 -105

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Seattle Genetics's earnings are expected to grow significantly at over 20% yearly.
  • Seattle Genetics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGS:SGEN Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 15 Analyst Estimates (S&P Global) See Below

All data from Seattle Genetics Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:SGEN Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 4.34 6.72 2.62 8.00
2022-12-31 2.36 3.90 0.89 8.00
2021-12-31 0.55 2.19 -0.91 11.00
2020-12-31 -0.54 0.49 -1.73 14.00
2019-12-31 -1.13 -0.88 -1.44 15.00
NasdaqGS:SGEN Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -0.78
2018-12-31 -1.41
2018-09-30 -1.06
2018-06-30 -0.30
2018-03-31 -1.22
2017-12-31 -0.88
2017-09-30 -0.85
2017-06-30 -1.43
2017-03-31 -1.27
2016-12-31 -1.00
2016-09-30 -0.78
2016-06-30 -0.76

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Seattle Genetics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Seattle Genetics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Seattle Genetics has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

SGEN Past Performance

  How has Seattle Genetics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Seattle Genetics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Seattle Genetics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Seattle Genetics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Seattle Genetics's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Seattle Genetics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Seattle Genetics Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:SGEN Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 709.31 -124.31 275.19
2018-12-31 654.70 -222.69 252.60
2018-09-30 609.79 -162.09 221.58
2018-06-30 575.66 -44.62 204.09
2018-03-31 513.71 -177.26 186.51
2017-12-31 482.25 -125.53 167.23
2017-09-30 457.92 -121.47 160.16
2017-06-30 428.94 -203.24 155.33
2017-03-31 416.12 -179.62 147.90
2016-12-31 418.15 -140.11 139.25
2016-09-30 406.35 -109.83 131.51
2016-06-30 384.11 -104.52 126.35
2016-03-31 365.80 -119.27 123.41
2015-12-31 336.80 -120.49 125.78
2015-09-30 317.65 -122.31 121.58
2015-06-30 309.43 -111.44 117.24
2015-03-31 300.64 -81.53 112.42
2014-12-31 286.76 -76.14 104.32
2014-09-30 279.84 -65.13 100.37
2014-06-30 274.96 -73.25 96.48
2014-03-31 280.21 -62.56 94.49
2013-12-31 269.26 -62.52 92.35
2013-09-30 265.77 -57.45 90.28
2013-06-30 244.63 -47.41 87.68
2013-03-31 219.90 -57.75 84.00
2012-12-31 210.81 -53.78 84.30
2012-09-30 195.79 -70.35 85.84
2012-06-30 166.62 -97.38 86.80

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Seattle Genetics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Seattle Genetics has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Seattle Genetics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Seattle Genetics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Seattle Genetics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

SGEN Health

 How is Seattle Genetics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Seattle Genetics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Seattle Genetics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Seattle Genetics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Seattle Genetics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Seattle Genetics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Seattle Genetics Company Filings, last reported 2 months ago.

NasdaqGS:SGEN Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 1,313.41 67.04 418.30
2018-12-31 1,273.94 0.00 410.67
2018-09-30 1,364.52 0.00 463.08
2018-06-30 1,382.44 0.00 447.98
2018-03-31 1,279.34 0.00 399.92
2017-12-31 677.57 0.00 413.17
2017-09-30 659.71 0.00 450.40
2017-06-30 573.53 0.00 452.41
2017-03-31 603.38 0.00 506.40
2016-12-31 634.09 0.00 588.99
2016-09-30 662.29 0.00 591.80
2016-06-30 668.52 0.00 608.95
2016-03-31 684.11 0.00 609.49
2015-12-31 685.91 0.00 649.65
2015-09-30 696.24 0.00 736.45
2015-06-30 179.62 0.00 249.54
2015-03-31 209.29 0.00 296.01
2014-12-31 210.83 0.00 313.41
2014-09-30 225.19 0.00 339.56
2014-06-30 225.83 0.00 349.21
2014-03-31 230.99 0.00 355.36
2013-12-31 230.19 0.00 374.27
2013-09-30 234.38 0.00 373.85
2013-06-30 237.12 0.00 338.09
2013-03-31 233.27 0.00 344.13
2012-12-31 226.15 0.00 364.26
2012-09-30 222.58 0.00 313.93
2012-06-30 218.52 0.00 330.34
  • Seattle Genetics has no debt.
  • Seattle Genetics has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Seattle Genetics has sufficient cash runway for 2.9 years based on current free cash flow.
  • Seattle Genetics has sufficient cash runway for 2.7 years if free cash flow continues to grow at historical rates of 11.8% each year.
X
Financial health checks
We assess Seattle Genetics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Seattle Genetics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

SGEN Dividends

 What is Seattle Genetics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Seattle Genetics dividends. Estimated to be 0% next year.
If you bought $2,000 of Seattle Genetics shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Seattle Genetics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Seattle Genetics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGS:SGEN Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 15 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 19 Stocks 2.4%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2011 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.5%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGS:SGEN Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 2.00
2019-12-31 0.00 2.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Seattle Genetics has not reported any payouts.
  • Unable to verify if Seattle Genetics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Seattle Genetics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Seattle Genetics has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Seattle Genetics's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess Seattle Genetics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Seattle Genetics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Seattle Genetics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

SGEN Management

 What is the CEO of Seattle Genetics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Clay Siegall
COMPENSATION $18,107,037
AGE 57
TENURE AS CEO 16.6 years
CEO Bio

Dr. Clay B. Siegall, Ph.D. co-founded Seattle Genetics, Inc. in 1997 and has been its Chief Executive Officer since November 2002 and its President since June 2000. Dr. Siegall has nearly 20 years of experience in cancer research and therapeutic drug development. He served as Executive Vice President of Seattle Genetics Inc., from December 1997 to June 2000 and Chief Scientific Officer from December 1997 to November 2002. Dr. Siegall was with the Bristol-Myers Squibb Pharmaceutical Research Institute as a Senior Research Investigator from February 1991 to January 1995 and as a Principal Scientist from January 1995 to December 1997. Dr. Siegall has been the Chairman of Seattle Genetics, Inc. since March 2004. He has been a Director of Ultragenyx Pharmaceutical Inc. since January 30, 2014. He has been a Director of Seattle Genetics Inc. since December 1997 and Alder Biopharmaceuticals Inc. since November 2005. He serves as a Director of Washington Biotechnology and Biomedical Association (WBBA) as well as on the Board of Governors of the Fred Hutchinson Cancer Research Business Alliance. He served as a Non Executive Director of Mirna Therapeutics, Inc. since January 30, 2013 until December 31, 2016. From February 1988 to February 1991, he was a Staff Fellow and Biotechnology Fellow at the National Cancer Institute, National Institutes of Health. Dr. Siegall has authored 67 scientific papers and holds nine patents. He serves on the Editorial Board of three scientific journals and is a member of the Board of Scientific Counselors for the Cancer Treatment Research Foundation. He was given the Pierce Award in 1995 for his efforts in the field of targeted toxins. In 2002, he was an Ernst & Young Pacific Northwest Entrepreneur of the Year award finalist in the healthcare category. Dr. Siegall received a Ph.D. in Genetics from George Washington University and a B.S. in Zoology from the University of Maryland.

CEO Compensation
  • Clay's compensation has increased whilst company is loss making.
  • Clay's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Seattle Genetics management team in years:

4.1
Average Tenure
57
Average Age
  • The tenure for the Seattle Genetics management team is about average.
Management Team

Clay Siegall

TITLE
Co-Founder
COMPENSATION
$18M
AGE
57
TENURE
16.6 yrs

Todd Simpson

TITLE
Chief Financial Officer
COMPENSATION
$4M
AGE
57
TENURE
13.7 yrs

Vaughn Himes

TITLE
Chief Technology Officer
COMPENSATION
$4M
AGE
57
TENURE
2.8 yrs

Roger Dansey

TITLE
Chief Medical Officer
COMPENSATION
$10M
AGE
61
TENURE
1.1 yrs

Jean Liu

TITLE
General Counsel
COMPENSATION
$2M
AGE
50
TENURE
4.6 yrs

Peggy Pinkston

TITLE
VP of Investor Relations & Executive Director of Corporate Communications

Natasha Hernday

TITLE
Senior Vice President of Corporate Development
AGE
46
TENURE
8.2 yrs

Matt Skelton

TITLE
Vice President of Marketing
TENURE
3.6 yrs

Chris Pawlowicz

TITLE
Executive Vice President of Human Resources

Dennis Benjamin

TITLE
Senior Vice President of Translational Research
TENURE
2.7 yrs
Board of Directors Tenure

Average tenure and age of the Seattle Genetics board of directors in years:

14.3
Average Tenure
57
Average Age
  • The average tenure for the Seattle Genetics board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Felix Baker

TITLE
Lead Independent Director
COMPENSATION
$510K
AGE
49
TENURE
14.3 yrs

Clay Siegall

TITLE
Co-Founder
COMPENSATION
$18M
AGE
57
TENURE
15.3 yrs

Dave Gryska

TITLE
Director
COMPENSATION
$485K
AGE
63
TENURE
14.3 yrs

Nancy Simonian

TITLE
Director
COMPENSATION
$475K
AGE
57
TENURE
7.3 yrs

Marc Lippman

TITLE
Director
COMPENSATION
$470K
AGE
73
TENURE
19 yrs

Srini Akkaraju

TITLE
Director
COMPENSATION
$465K
AGE
50
TENURE
15.9 yrs

Dan Welch

TITLE
Independent Director
COMPENSATION
$477K
AGE
60
TENURE
12 yrs

John Orwin

TITLE
Director
COMPENSATION
$483K
AGE
53
TENURE
5.4 yrs

Alpna Seth

TITLE
Director
COMPENSATION
$729K
AGE
55
TENURE
1.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
30. Nov 18 Sell Darren Cline Individual 29. Nov 18 29. Nov 18 -7,000 $62.88 $-440,160
21. Nov 18 Sell Darren Cline Individual 21. Nov 18 21. Nov 18 -4,167 $56.68 $-236,204
24. Aug 18 Sell Clay Siegall Individual 21. Aug 18 21. Aug 18 -25,000 $74.95 $-1,873,750
03. Aug 18 Sell Marc Lippman Individual 31. Jul 18 31. Jul 18 -7,400 $69.25 $-512,450
X
Management checks
We assess Seattle Genetics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Seattle Genetics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

SGEN News

Simply Wall St News

Are Investors Undervaluing Seattle Genetics, Inc. (NASDAQ:SGEN) By 30%?

Today, we will estimate the stock's intrinsic value by projecting its future cash flows and then discounting them to today's value. … Generally we assume that a dollar today is more valuable than a dollar in the future, so we need to discount the sum of these future cash flows to arrive at a present value estimate: 10-year free cash flow (FCF) forecast 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 Levered FCF ($, Millions) $-130.00 $144.95 $351.10 $484.73 $812.16 $1.09k $1.36k $1.61k $1.82k $2.01k Growth Rate Estimate Source Analyst x3 Analyst x2 Analyst x2 Analyst x2 Analyst x2 Est @ 34.19% Est @ 24.75% Est @ 18.14% Est @ 13.52% Est @ 10.28% Present Value ($, Millions) Discounted @ 10.25% $-117.92 $119.26 $262.02 $328.13 $498.68 $606.97 $686.82 $736.02 $757.88 $758.13 Present Value of 10-year Cash Flow (PVCF)= $4.64b "Est" = FCF growth rate estimated by Simply Wall St After calculating the present value of future cash flows in the intial 10-year period, we need to calculate the Terminal Value, which accounts for all future cash flows beyond the first stage. … NasdaqGS:SGEN Intrinsic value, June 3rd 2019 Important assumptions Now the most important inputs to a discounted cash flow are the discount rate, and of course, the actual cash flows.

Simply Wall St -

Seattle Genetics, Inc. (NASDAQ:SGEN) Insiders Have Been Selling

NasdaqGS:SGEN Recent Insider Trading, May 14th 2019 I will like Seattle Genetics better if I see some big insider buys. … Insider Ownership of Seattle Genetics I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. … Seattle Genetics insiders own 1.0% of the company, currently worth about US$105m based on the recent share price.

Simply Wall St -

Should You Worry About Seattle Genetics, Inc.'s (NASDAQ:SGEN) CEO Salary Level?

This analysis aims first to contrast CEO compensation with other large companies. … How Does Clay Siegall's Compensation Compare With Similar Sized Companies. … is worth US$11b, and total annual CEO compensation is US$8.6m.

Simply Wall St -

Breakeven On The Horizon For Seattle Genetics, Inc. (NASDAQ:SGEN)

Seattle Genetics, Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. … The US$12b market-cap company announced a latest loss of -US$222.7m on 31 December 2018 for its most recent financial year result. … Check out our latest analysis for Seattle Genetics

Simply Wall St -

If You Had Bought Seattle Genetics Shares Three Years Ago You'd Have Made 113%

It's also good to see the share price up 12% over the last quarter. … Seattle Genetics isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. … When a company doesn't make profits, we'd generally expect to see good revenue growth.

Simply Wall St -

Is Seattle Genetics, Inc. (NASDAQ:SGEN) A Financially Strong Company?

With a market capitalization of US$12b, Seattle Genetics, Inc. … Common characteristics for these big stocks are their strong balance sheet and high market liquidity, which means there's plenty of stocks available to the public for trading. … Using the most recent data for SGEN, I will determine its financial status based on its solvency and liquidity, and assess whether the stock is a safe investment.

Simply Wall St -

Does Seattle Genetics, Inc.'s (NASDAQ:SGEN) CEO Pay Matter?

First, this article will compare CEO compensation with compensation at similar sized companies. … How Does Clay Siegall's Compensation Compare With Similar Sized Companies. … has a market capitalization of US$9.5b, and pays its CEO total annual compensation worth US$8.6m.

Simply Wall St -

Need To Know: Seattle Genetics, Inc. (NASDAQ:SGEN) Insiders Have Been Selling Shares

But logic dictates you should pay some attention to whether insiders are buying or selling shares. … Seattle Genetics Insider Transactions Over The Last Year. … In total, Seattle Genetics insiders sold more than they bought over the last year

Simply Wall St -

Has Seattle Genetics Inc (NASDAQ:SGEN) Got Enough Cash?

Small-caps and large-caps are wildly popular among investors, however, mid-cap stocks, such as Seattle Genetics Inc (NASDAQ:SGEN), with a market capitalization of US$8.8b, rarely draw their attention from the investing community. … Let’s take a look at SGEN’s debt concentration and assess their financial liquidity to get an idea of their ability to fund strategic acquisitions and grow through cyclical pressures. … Note that this information is centred entirely on financial health and is a top-level understanding, so I encourage you to look further.

Simply Wall St -

Breakeven On The Horizon For Seattle Genetics Inc (NASDAQ:SGEN)

Seattle Genetics, Inc., a biotechnology company, focuses on the development and commercialization of targeted therapies for the treatment of cancer worldwide. … With the latest financial year loss of -US$126m and a trailing-twelve month of -US$45m, the US$12.2b market-cap alleviates its loss by moving closer towards its target of breakeven? … View our latest analysis for Seattle Genetics

Simply Wall St -

SGEN Company Info

Description

Seattle Genetics, Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas. It also conducts various clinical trials to evaluate the combination of ADCETRIS and nivolumab to treat patients with relapsed or refractory, or transplant-ineligible, advanced classical Hodgkin lymphoma; relapsed or refractory B-cell and T-cell non-Hodgkin lymphomas; second-line Hodgkin lymphoma; and relapsed/refractory classical Hodgkin lymphoma, as well as to treat Hodgkin lymphoma in patients with age 60 years or older. In addition, the company develops Enfortumab vedotin, ADC composed of an anti-Nectin-4 monoclonal antibody to treat bladder cancer, and ovarian and lung cancers; Tucatinib, an oral tyrosine kinase inhibitor for HER2-positive metastatic breast cancer; and Tisotumab Vedotin, an ADC composed of a human antibody that binds to tissue factor to treat various solid tumors, including cervical, ovarian, prostate, and bladder. Further, it develops early-stage clinical product candidates comprising ladiratuzumab vedotin, an ADC targeting LIV-1 and metastatic triple-negative breast cancer; SGN-CD48A; SEA-BCMA for patients with relapsed or refractory multiple myeloma; and SGN-2FF for patients with advanced solid tumors. It has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline LLC; Progenics Pharmaceuticals Inc.; Unum Therapeutics, Inc.; Pieris Pharmaceuticals, Inc.; Pieris Pharmaceuticals AG; Takeda Pharmaceutical Company Limited; Astellas Pharma, Inc.; and Agensys, Inc. Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.

Details
Name: Seattle Genetics, Inc.
SGEN
Exchange: NasdaqGS
Founded: 1998
$11,050,051,675
161,314,623
Website: http://www.seattlegenetics.com
Address: Seattle Genetics, Inc.
21823 30th Drive SE,
Bothell,
Washington, 98021,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS SGEN Common Shares Nasdaq Global Select US USD 07. Mar 2001
DB SGT Common Shares Deutsche Boerse AG DE EUR 07. Mar 2001
Number of employees
Current staff
Staff numbers
1,302
Seattle Genetics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/06/15 23:44
End of day share price update: 2019/06/14 00:00
Last estimates confirmation: 2019/06/12
Last earnings filing: 2019/04/26
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.